FDA data indicate expenditure by pharmaceutical companies on R&D has doubled since 1996. Why is intensive research yielding so few patented inventions and so few new drugs?
Thomas Hays
Advertisement
Articles by Thomas Hays
Advertisement
Latest Updated Articles
Talking Point: The patent problem with metabolitesPublished: March 1st 2006 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
PharmTech Weekly News Roundup – Week of November 3, 2025
3
AAPS PharmSci 360 2025: Trends in Bioanalysis
4
How AI, Machine Learning, and Large Language Models Enhance Bioanalysis
5
